about
Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysisInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionFinally sofosbuvir: an oral anti-HCV drug with wide performance capabilityPrediction of fibrosis progression in chronic viral hepatitisIs sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?Emerging concepts in immunity to hepatitis C virus infection.Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseasesMicroRNAs in inflammatory bowel disease--pathogenesis, diagnostics and therapeuticsHigh prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patientsNew preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replicationOutlier populations: individual and social network correlates of solvent-using injection drug usersBaseline HCV Antibody Prevalence and Risk Factors among Drug Users in China's National Methadone Maintenance Treatment ProgramIs Hepatitis C Infection Associated With a Higher Risk of Complications After Total Shoulder Arthroplasty?Discovering feature relevancy and dependency by kernel-guided probabilistic model-building evolutionViruses and human cancers: a long road of discovery of molecular paradigms.Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-κB complexExtracellular HCV-core protein induces an immature regulatory phenotype in NK cells: implications for outcome of acute infectionSequence-based in silico analysis of well studied hepatitis C virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgroundsCharacteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C.A Smartphone Application Supporting Recovery from Heroin Addiction: Perspectives of Patients and Providers in China, Taiwan, and the USAHepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and signal transducer and activator of transcription (STAT) 1 protein expression.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Direct-acting antiviral agents and the path to interferon independence.Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver diseaseColonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam.Complementary and alternative medications in hepatitis C infection.Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C.Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cellsViral carcinogenesis: factors inducing DNA damage and virus integrationTargeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WEThe changing burden of hepatitis C virus infection in the United States: model-based predictions.Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesThe common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perceptionFinal Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
P2860
Q24186846-3FA4C7A1-CB24-4199-ADD4-99EDC9E23885Q26746563-88884226-A1BC-46FD-AE5D-E949E5130871Q26822400-953FC4F1-5E5D-4DB5-9CCC-5BE0E7006A6FQ26823671-23FAE475-3481-490B-B4C3-20A81F84151DQ26830804-EF20C97C-E948-4B5D-9ECE-C20C4D6866EFQ27002588-E648679A-DED0-4B7E-83A8-74CC20D35AE4Q27011249-61067258-3964-4976-AAE1-183C440B94CEQ27025092-8C567246-E25B-426B-BFC4-763BC03DB220Q28481558-85646132-CEA3-4AD6-930A-CE30EA0C12D7Q28536288-D86D26AF-FE01-44CD-9DFA-12BEAA536F8EQ28539716-C2754D6E-5AD6-4D6B-89C7-21F5350BB528Q28550339-BD716024-F4A8-4250-BE5E-C98F8030623EQ30275569-63B564FE-9859-404E-93DB-259CA0080C3BQ30360514-3F422AF0-86FD-42F2-9C8D-22A05BA7C2D0Q30384388-AF8AE1C8-3A61-4763-9CA2-D0FDCCCB8B86Q30407935-E4807884-7CDA-4E94-8C6E-8EDA9E780676Q30411437-3BAB6E84-6EDF-4D3B-968B-49DD11D24465Q30532816-97064D7D-8676-4642-B169-103DFED95D0AQ33408423-0C314D1F-CCD2-4076-9EEC-77C00F0AAF9CQ33447050-5EFC31F8-863D-4897-8AE5-13B404F98137Q33553433-3CBC58E7-5499-472C-883E-054743BE6C70Q33559298-16BB659B-04C8-4E56-B8C2-3AF3BAFF4B18Q33727347-F313E09D-700C-4E11-9E60-CF185A8CEB57Q33795637-89C381E6-F01A-4E23-AE46-7093AFA32C42Q34264303-D39D0EDA-A7C5-42E2-A9DC-163B511FF5B2Q34411345-DD9F301A-74A2-4990-9EEC-88DC4C67DAFEQ34586112-F75D5486-8C57-4F3E-A3CE-86904D11D290Q34626547-E2FA72FA-BC9A-4FD8-9CA8-D229094752CDQ34699732-97E14381-C83D-4878-AC33-6DF2A2E55D76Q34774880-D77CAFFD-F92C-4BA2-9B19-ABA492DAAB65Q35022356-B579F7F9-8C2F-4F22-BE73-880B6A00747AQ35168083-B1EBBB78-68C9-453F-9D9F-37B7AED20A4CQ35531664-C7CB05F9-C6B9-42D9-A69B-C3AA42AE15C8Q35597464-4A1B33FE-2C14-4992-9E57-B363106DFB3DQ35619161-639AE071-6603-4F71-BC95-7B9D8D63593DQ35770129-C22E1308-87CD-4FFB-AAEE-BEE8761B4CD6Q35785198-8BA78B35-1131-4AD9-990C-B211629AF631Q35803105-D113421F-8DF0-484B-95BC-DE5E6C95B1AAQ35843159-D8EA0445-6C32-4776-831D-D40A7330863BQ35860136-F6DD35A8-BD94-4C93-857B-8733A1788F54
P2860
description
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2011
@ast
im Juni 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 23 June 2011)
@en
vedecký článok (publikovaný 2011/06/23)
@sk
vědecký článek publikovaný v roce 2011
@cs
wetenschappelijk artikel (gepubliceerd op 2011/06/23)
@nl
наукова стаття, опублікована в червні 2011
@uk
مقالة علمية (نشرت في 23-6-2011)
@ar
name
Clinical practice. Chronic hepatitis C infection
@ast
Clinical practice. Chronic hepatitis C infection
@en
Clinical practice. Chronic hepatitis C infection
@nl
type
label
Clinical practice. Chronic hepatitis C infection
@ast
Clinical practice. Chronic hepatitis C infection
@en
Clinical practice. Chronic hepatitis C infection
@nl
prefLabel
Clinical practice. Chronic hepatitis C infection
@ast
Clinical practice. Chronic hepatitis C infection
@en
Clinical practice. Chronic hepatitis C infection
@nl
P3181
P356
P1476
Clinical practice. Chronic hepatitis C infection
@en
P2093
Hugo R Rosen
P304
P3181
P356
10.1056/NEJMCP1006613
P407
P577
2011-06-23T00:00:00Z